Moderna Full Approval

News Update

Moderna joins Pfizer, seeks full FDA approval

By Gwen Baumgardner (Reporter)

Moderna announced Tuesday it is filing for full U.S. Food and Drug Administration (FDA) approval of its COVID-19 vaccine.

Right now, the vaccine is only authorized for emergency use.

Full approval would allow Moderna to market the vaccine directly. Approval could also help curb vaccine hesitancy.

Moderna said it will submit data to the FDA on a rolling basis over the coming weeks. The FDA will tell Moderna when their data has been accepted for review.

Pfizer sought full approval for its vaccine last month.

Gwen Baumgardner: WE’VE GOT BREAKING NEWS ABOUT MODERNA’S COVID VACCINE.
I’M GWEN BAUMGARDNER WITH STRAIGHT ARROW NEWS.
THIS MORNING — MODERNA ANNOUNCED IT IS SEEKING FULL U-S APPROVAL FOR ITS COVID-19 VACCINE.

RIGHT NOW — THE VACCINE IS ONLY AUTHORIZED FOR EMERGENCY USE IN THE U-S.
FULL APPROVAL WOULD ALLOW MODERNA TO MARKET THE VACCINE DIRECTLY.
MODERNA SAYS IT WILL SUBMIT DATA TO THE F-D-A OVER THE COMING WEEKS…TO START THE APPROVAL PROCESS.

LAST MONTH — PFIZER ANNOUNCED IT WAS SEEKING THE SAME FULL APPROVAL OF ITS VACCINE.
FOR MORE BREAKING NEWS THROUGHOUT THE DAY — STICK WITH STRAIGHT ARROW NEWS DOT COM.

Rate the bias meter to unlock commenting

lock

Watch the video to unlock rating

Your Rating

Rating closes in 4 days

Community Rating

eye icon

Rate to reveal

Community ratings are revealed after you rate the story.

Join the conversation!


Community Rating

Community ratings are revealed after you rate the story.

lock

Watch the video to unlock rating

Rate the bias

Keep us honest! Let us know if you thought this video was neutral or biased.

Rate the bias meter to unlock commenting

Moderna announced Tuesday it is filing for full U.S. Food and Drug Administration (FDA) approval of its COVID-19 vaccine.

Right now, the vaccine is only authorized for emergency use.

Full approval would allow Moderna to market the vaccine directly. Approval could also help curb vaccine hesitancy.

Moderna said it will submit data to the FDA on a rolling basis over the coming weeks. The FDA will tell Moderna when their data has been accepted for review.

Pfizer sought full approval for its vaccine last month.